Experiences with
MabThera40 public posts
Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients
In addition, they may experience:
• Treatment-related immunodeficiency (such as that resulting from anti-CD20 monoclonal antibody treatment such as Rituximab (Mabthera/Rituxan), Obinutuzumab (Gazyva) or ofatumumab (Arzerra)
In a recent study, ‘individual risk factors associated with a poor prognosis
Want to take advantage of all our features? Just log in!
or
Explainer: what is chemotherapy and how does it work?
Mabthera/Rituximab, Gazyva/Obinutuzumab) and the increased development of personalised medicine.
Neil
Photo: Correa wildflower
‘Tis the season for food poisoning: a Christmas warning
So please, have a safe and enjoyable Christmas by being careful what you eat, taking particular care to avoid foods that have not been adequately refrigerated and for those under treatment or recently treated with anti-CD20 antibodies like Rituximab/Mabthera or Gazyva/Obinutuzumab, foods not recommended
Statistical analysis of REACH trial patients identifies Progression Free Survival prognostic factor for FCR patients
REACH (NCT0090051) was an open-label randomized (1:1) phase III trial in relapsed CLL comparing FC with FCR, (that is comparing traditional chemotherapy using Fludarabine+Cyclophosphamide, compared to immunochemotherapy in which the monoclonal CD20 antibody Rituximab/Mabthera is added to the Fludarabine
Rituximab hailed as a breakthrough for millions with Chronic Fatigue
This related article in New Scientist explains that it is [u]Rituximab/Mabthera[/u], the monoclonal antibody that is used with many CLL treatments to provide deeper and longer remissions and for some of us, the possibility of a cure with FCR:
Antibody wipeout relieves symptoms of chronic fatigue syndrome
How Monoclonal Antibodies produce lasting antitumour effects
This Hematology times article examines research into how CD 20 Monoclonal Antibodies such as Mabthera®/Rituximab/Rituxan (the R in FCR) and obinutuzumab/GAZYVA®, trigger macrophages to engulf and destroy our B-CLL cells when we are treated with immunochemotherapy.